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Abstract
Prostate cancer continues to occur in over 230,000 men each year. Although the majority of these
will be diagnosed in the early stages, there remains a proportion who will either be diagnosed in
late stage disease or develop progressive disease. In patients with advanced disease, research has
recently focused on using chemotherapy for symptom management and palliation. Given that the
focus is not on cure, the effect of chemotherapy on quality of life is of utmost importance. The
present article will 1) summarize the current chemotherapeutic studies that have included a quality
of life component, with a particular focus on pain and fatigue, 2) discuss the issue of distress in
advanced prostate cancer patients treated with chemotherapy, and 3) suggest future research
directions.
From the studies that have investigated quality of life, it appears that several chemotherapeutic
agents reduce pain and fatigue, although the development of fatigue is often the dose-limiting factor
of some agents. The assessment of overall quality of life has occurred in several studies, however,
an examination into the impact of chemotherapy on functional status and interpersonal
relationships has not been studied. Finally, in contrast to the numerous studies in early stage
prostate cancer patients, the presence and effect of distress in chemotherapy-treated prostate
patients has not been examined. As such, increased attention is needed to quality of life during
phase I-III chemotherapy trials.
Background and significance
Prostate cancer will be diagnosed in an estimated 230,110
men during 2004 [1]. There will also be approximately
29,900 men who will die from prostate cancer this year,
making it the second leading cause of cancer death among
men. While early detection and improved treatments have
resulted in improved 5-year survival rates for individuals
with early stage prostate cancer (recent data have put the
5-year survival rates at 100% for men diagnosed with local
and regional prostate cancer), there remains a proportion
of men (roughly 14%) who will be diagnosed with
advanced prostate cancer. For these individuals, the 5-year
survival rate is much lower. Indeed only 34% of men diag-
nosed with distant disease will survive for 5 years [1].
For men with late stage disease, chemotherapy is increas-
ingly being examined as a treatment option, although the
goal is usually palliative in nature and may not extend
length of survival [2,3]. Chemotherapy is also being
explored as adjuvant therapy in men with early stage
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disease where length of survival may be lengthened by its
administration. In both cases, but particularly among
men receiving chemotherapy as treatment for advanced
cancer, the effect that chemotherapy may have on quality
of life (QOL) is extremely important. This QOL includes
not only the individual's physical well-being, but their
mental well-being, role functioning and levels of emo-
tional distress as well. At present, few studies have exam-
ined the impact of chemotherapy on the physical and
emotional QOL of prostate cancer patients. The goals of
the current article are to: 1) summarize the current chem-
otherapeutic studies that have included a quality of life
component, with a particular focus on pain and fatigue,
2) discuss the issue of distress in advanced prostate cancer
patients treated with chemotherapy, and 3) suggest future
research directions.
Impact of chemotherapy on quality of life
The inclusion of QOL endpoints in chemotherapy trials
with cancer patients started in earnest during the last dec-
ade, with the majority of studies assessing the impact of
chemotherapeutic agents on symptoms such as pain and
fatigue. Since then, the inclusion of QOL endpoints has
become a more common outcome in chemotherapy stud-
ies, although many continue to neglect the psychological
component, focusing instead on the occurrence of symp-
toms and their impact on physical QOL.
Methods
A comprehensive search of English-language articles in
PubMed was conducted to identify studies that had
assessed quality of life and/or emotional distress as part of
chemotherapeutic trials in advanced cancer patients
(Table 1). The keywords "advanced cancer", "chemother-
apy", and "quality of life" were included in each search. In
subsequent searches "distress", "anxiety", and "depres-
sion" were added.
Pain
In one of the first studies to examine the impact of chem-
otherapy on pain, Tannock, Osoba, Stockler et al. [4] ran-
domized 161 hormone-resistant prostate cancer patients
either to prednisolone or prednisolone plus mitox-
antrone. The goal was to determine the impact on pain
reduction as a palliative endpoint. Also included was the
overall assessment of QOL using the EORTC QLQ-30 and
a specific prostate cancer QOL measure composed of nine
analog scales. The results demonstrated that the addition
of mitoxantrone to prednisolone reduced pain in 29% of
patients compared to 10% for those who only received
prednisolone. Improvements in pain, mood, and physical
activity were also observed on the QOL measures for the
individuals who received mitoxantrone. Additional anal-
yses from this study revealed that after six weeks of treat-
ment, pain and physical functioning remained improved
in the mitoxantrone plus prednisone group. Moreover,
after 12 weeks of treatment, overall quality of life in this
group was improved, as was quality of life in four
functional domains and nine specific symptoms [5].
Additional studies with mitoxantrone have demonstrated
that up to 40% of patients will report reductions in pain
and improvements in QOL [6]. As a result, in hormone-
resistant prostate cancer patients, mitoxantrone is
believed to be of some benefit [4].
Pain was also assessed in several studies utilizing
docetaxel either alone or in combination with estramus-
tine in androgen-independent prostate cancer [7-9]. In
one study, the administration of docetaxel as a single
agent resulted in pain relief, defined as two-point reduc-
tion in the Present Pain Intensity scale on two consecutive
Table 1: Summary of reviewed articles
Authors Chemotherapeutic agent QOL measure Direction of effect
Tannock et al. (1996) Mitoxantrone EORTC QLQ-30; Pain rating Improved pain, mood & physical activity
Beer et al., (2001) Docetaxel Present Pain Intensity scale Improved pain
Sinibaldi et al. (1999) Docetaxel Brief Pain Inventory Improved pain
Copur et al. (2001) Docetaxel Numeric rating scale Improved pain
Gravis et al. (2003) Docetaxel EORTC QLQ-30; Pain VAS Improved role, social functioning, overall QOL, 
pain, fatigue, constipation
Small et al. (2000) Suramin Brief Pain Inventory Improved pain
Fuse et al. (1996) Cisplatin/carboplatin Rating scale Improved pain
Kreis et al. (1999). Docetaxel Physician-graded events Presence of fatigue dose-limiting factor
Hamilton et al. (2003) Vinblastine Physician-graded events Presence of fatigue dose-limiting factor
van Andel et al. (2003) Epirubicin QLQ-30 Reduced fatigue, transient improvement in 
emotional, social and cognitive functioning
Kornblith et al. (2001) Docetaxel FACT-P, Mental Health Inventory-17 Transient improvements in emotional well-being, 
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evaluations, in 30% of patients [10]. Moreover, an addi-
tional 18% reduced their consumption of analgesics by at
least 50%. Mean pain scores on quality of life scales were
also reduced over the course of treatment [7]. In two stud-
ies using the combination of docetaxel and estramustine,
pain reductions were observed in 70% and 82% of
patients [8,9]. Unfortunately, the methods used to assess
pain are not thoroughly reported in either study.
In a recent study, docetaxel was administered intrave-
nously on a daily basis for 6 consecutive weeks followed
by a 2-week break between each of up to 4 cycles [11]. The
authors assessed QOL prior to the start of chemotherapy,
the first day of each treatment cycle, and then 15 and 30
days after the last treatment. At baseline, metastatic, hor-
mone-refractory prostate cancer patients reported
decreased QOL in role, social functioning, and overall
QOL, as well as pain, fatigue, and constipation. Of note,
following the first cycle, all patients reported improved
QOL and pain relative to baseline levels. At the end of
treatment, pain levels had increased somewhat, but were
still lower than baseline levels. Combined, these studies
suggest that docetaxel is effective in reducing pain in
androgen-independent patients.
Reductions in pain have also been observed in studies
using suramin and epirubicin. In a study by Small et al.
[12], comparing suramin plus hydrocortisone to a pla-
cebo plus hydrocortisone, reduction in pain for longer
durations were observed in the suramin treated group.
Interestingly, however, more global measures of QOL
were not impacted by that treatment. Despite the reduc-
tion in pain, because overall QOL and survival rates are
similar to hydrocortisone treated patients, whether
suramin should be regularly used in the treatment of hor-
mone-refractory prostate cancer patients is unclear. This is
also true for suramin with anthracycline regimens, where
the combination, because it does not offer significant
improvements in disease management, is not recom-
mended to hormone-resistant prostate cancer patients
[13-18]. Pain reduction has also been observed in prostate
cancer patients treated with epirubicin [19]. Interestingly,
the reductions in pain did not correspond to patient-
reported improvements in QOL. As a result, like suramin,
the authors concluded that epirubicin should not be used
as a monotherapy.
The use of the more commonly known platinum com-
pounds (e.g., cisplatin, carboplatin) have also demon-
strated beneficial efforts on pain reduction. In advanced
prostate cancer patients treated with a carboplatin/epiru-
bicin/etoposide regimen, pain relief was observed in 44%
of the patients [20].
The overall point of these studies is that for prostate can-
cer patients with advanced disease, there are a variety of
chemotherapeutic agents that have beneficial palliative
effects, specifically pain reduction. Despite this, there is
no definitive palliative pain regimen in this population
and no defined algorithm for pain management using
chemotherapy.
Fatigue
Several studies have investigated the relationship between
chemotherapeutic agents and fatigue in prostate cancer
patients. Among the agents studied are the taxanes, specif-
ically docetaxel and paclitaxel. In phase I studies of
docetaxel and estramustine, the presence of fatigue has
been used to identify the dose-limiting factor [21,22].
Currently, a phase III trial is underway to determine the
impact on QOL of docetaxel/estramustine compared with
mitoxantrone/prednisolone [23]. In a similar phase I/II
study examining the effect of vinblastine for androgen-
independent prostate cancer, fatigue was also reported as
the dose-limiting factor. More importantly, however, the
agent was found to be inactive resulting in the conclusion
that vinblastine is not an appropriate treatment [24].
Fatigue was also an endpoint in a well-designed study that
assessed the effect of 25 mg/m2 epirubicin administered
intravenously on a weekly basis compared to 100 mg/m2
administered every 4-weeks [19]. After four weeks of treat-
ment, individuals who were in the Epi100 group reported
less fatigue. They also reported better emotional, social,
and cognitive functioning as measured by QLQ-30,
although these differences disappeared at repeated assess-
ments. The effect of subsequent administration of either
dosage of epirubicin on fatigue was not reported,
although the authors note that there were no differences
at subsequent assessments between groups. As such, it is
unknown whether epirubicin decreases or increases
fatigue in prostate cancer patients over time.
Quality of Life (QOL)
In contrast to the numerous QOL studies of early-stage
prostate cancer patients, beyond pain and fatigue, the
assessment of QOL in advanced stage prostate cancer
patients is relatively lacking. By and large there are no
studies assessing the common areas of physical well-being
(e.g., urinary and sexual functioning) or psychological
well-being (e.g., distress related to treatment or sequelae),
and social or family well-being in chemotherapy treated
patients. The notable exception is a study of the QOL of
44 hormone refractory prostate cancer patients and their
partners by Kornblith et al. [25]. In a phase II study of
docetaxel, estramustine, and low dose hydrocortisone,
prostate cancer patients were assessed with the Functional
Assessment of Cancer Therapy-Prostate, as well as the
Mental Health Inventory-17. Over a period of 6-months,Health and Quality of Life Outcomes 2004, 2:37 http://www.hqlo.com/content/2/1/37
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men reported significant improvements on the Emotional
Well-being subscale. Further examination, however,
revealed that when compared to the baseline assessment,
emotional well-being was only better at the two and four
month assessments. Total FACT-P scores improved over
the course of treatment as well, as did prostate cancer-spe-
cific concerns, although the former was not significant
[25]. The authors concluded that the benefits of the chem-
otherapeutic regimen were limited to the first four-
months of treatment.
Impact of chemotherapy on emotional distress
In contrast to the various studies that have investigated
the presence of emotional distress, depression, and anxi-
ety in early stage prostate cancer patients, there is remark-
ably little concerning these issues in those with advanced
cancer. Indeed, a Pubmed search using the terms "distress
AND advanced prostate cancer" resulted in only 12 stud-
ies. Of these, only 3 studies specifically focused on
advanced prostate cancer [25-27], with 1 of these focusing
on physical symptom distress [26] and another focused
on a group of asymptomatic men with nonmetastatic
prostate cancer receiving androgen deprivation therapy
[27]. Only one of the studies, the previously cited Korn-
blith et al. [25] study assessed distress in chemotherapy
treated men. The result, therefore, is an overwhelming
lack of information concerning the emotional function-
ing of chemotherapy-treated prostate cancer patients. It is
hard to believe that these individuals who are frequently
androgen-deprived, have a short life expectancy, and are
being treated with chemotherapy for palliative purposes
are not experiencing some emotional distress. Even as part
of phase II studies, where the sample sizes are small, emo-
tional distress should be examined if for no other reason
than to provide initial information as to what changes
may be seen in a larger sample, and what issues need to be
assessed.
Conclusions and implications
Chemotherapy is being examined with greater frequency
in the treatment of advanced prostate cancer. Since the
goal of treatment for these individuals is more likely to be
palliation than cure, understanding the impact on QOL is
that much more important. For example, understanding
the impact on QOL can assist clinicians and patients in
decision-making by providing data on whether symptom
benefit obtained outweighs the toxicities from treatment.
Thus far, several studies have identified improvements in
pain and fatigue as a result of chemotherapeutic proto-
cols, although in some studies, the presence of fatigue is a
dose-limiting factor. Disappointing is the lack of focus on
the more global aspects of quality of life, the impact on
physical, psychological, social, and family well-being.
How the treatment of the individual affects their relation-
ships with others (e.g., marital relationship, sexual func-
tioning) has yet to be studied in this population. Also yet
to be studied is the impact on emotional well-being. The
presence of distress in cancer patients is well-documented
(e.g., [28]), and it is known that early-stage prostate cancer
patients exhibit distress (bother) over physical side effects
(i.e., urinary and sexual functioning). In addition, distress
related to PSA tests has been documented. What then is
the emotional well-being of advanced prostate cancers
like? Does the administration of chemotherapy play a role
in either the development of distress or its reduction? As
the continued development and testing of chemothera-
peutic medications for advanced prostate cancer moves
from phase I through phase II and III trials, it is of ever-
increasing importance to assess the impact on QOL and
distress. Only through its inclusion will a clearer picture of
the efficacy of chemotherapy be observed. Future research
can do this by developing protocols that include HRQOL
parameters as a standard part of the design process. Both
the industry that develops and tests the compound and
the academics who deliver it to the patient should be
involved in identifying which aspects of QOL are essential
to target.
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